drugset
drugset / Trial / NCT05889273

ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD)

NCT05889273 ↗

Phase 2 Active not recruiting 120 enrolled MapLight Therapeutics
NaSingle-groupOpen-labelTreatment

Summary

ML-004-003 is a multi-center, open-label extension study that will enroll approximately 120 adolescent and adult subjects with ASD that have completed study ML-004-002. The primary objective of the study will be to evaluate the safety of ML-004 in subjects with ASD.

Timeline

Start
2023-06-01
Primary completion
2027-11
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Subject ML-004 Unknown 12 mg Oral
Subject ML-004 Unknown 24 mg Oral
Subject ML-004 Unknown 48 mg Oral
Subject ML-004 Unknown 72 mg Oral

Indications

autism spectrum disorder